Market capitalization | $27.28m |
Enterprise Value | $28.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.58 |
P/S ratio (TTM) P/S ratio | 0.56 |
P/B ratio (TTM) P/B ratio | 10.40 |
Revenue growth (TTM) Revenue growth | -11.31% |
Revenue (TTM) Revenue | $48.43m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
1 Analyst has issued a forecast IRIDEX Corporation:
1 Analyst has issued a forecast IRIDEX Corporation:
Sep '24 |
+/-
%
|
||
Revenue | 48 48 |
11%
11%
|
|
Gross Profit | 18 18 |
21%
21%
|
|
EBITDA | -9.06 -9.06 |
50%
50%
|
EBIT (Operating Income) EBIT | -11 -11 |
31%
31%
|
Net Profit | -11 -11 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Patrick Mercer |
Employees | 111 |
Founded | 1989 |
Website | www.iridex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.